15 / 15
Page 65
Notes:
Pharmaceutica Analytica Acta | Volume: 09
September 20-22, 2018 Prague, Czech Republic
Pharmaceutics & Drug Delivery Systems
17
th
Annual Congress on
Pharm Anal Acta 2018, Volume: 9
DOI: 10.4172/2153-2435-C2-037
Dendrimer-based drug delivery system- focus on Indian visceral leishmaniasis
Pradeep Kumar
Amity University Rajasthan, India
L
eishmaniasis: a vector-borne disease has a worldwide existence. It presents mainly in four forms: visceral leishmaniasis, cutaneous
leishmaniasis, mucocutaneous leishmaniasis and post kala-azar dermal leishmaniasis (PKDL). In India, visceral leishmaniasis is
the most existence type of leishmaniasis. Visceral leishmaniasis is also known as kala-azar, black fever, dumdum fever, burdwan fever,
sarkari bimari etc. Visceral leishmaniasis is caused by Protozoa species haemoflagellate Leishmaniasis donovani and transmitted
by the bite of sand flies of Phlebotomus genus. Visceral leishmaniasis affects various age groups. Approximately, 10 k morbidity
with 1 k mortality occurs annually due to visceral leishmaniasis in India. Fast urbanization, poverty, improper sanitation, lack of
knowledge about prevention and individual risk factors like HIV, malnutrition and genetic susceptibility is the major source of
visceral leishmaniasis existence in India. Approximately, 90% cases of Indian visceral leishmaniasis come from Bihar. Available
treatment modalities have limitations like serious side effects, nonoral solubility, high cost and long hospitalization, due to this, a
favorable treatment option for visceral leishmaniasis is still out of range of a common man. A dendrimer is a new generation of
artificial polymeric macromolecules constructed in a step-by-step fashion using repetitive chemistry. Dendrimer has a number of
applications in several pharmaceutical fields such as enhancing the solubility of the poorly soluble drug, enhancing the delivery of
DNA, and as a carrier for the development of novel drug delivery systems. The present research emphasizes the development of a
conjugate of dendrimer with the nonoral soluble drug for the purpose of oral solubility enhancement and then use for the treatment
of visceral leishmaniasis.
Pradeepkalgar@gmail.com